

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company.



China Regenerative Medicine International Limited
中國再生醫學國際有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8158)

**APPROVAL BY THE SHENZHEN DEVELOPMENT AND
REFORM COMMISSION FOR THE ESTABLISHMENT OF
A SHENZHEN TISSUE ENGINEERING LABORATORY BY
A SUBSIDIARY OF CHINA REGENERATIVE MEDICINE
INTERNATIONAL LIMITED**

The “Shenzhen Tissue Engineering Laboratory Project” and the “Tissue Engineering Cornea Product Development and Commercialization Project” undertaken by Shenzhen AiNear Cornea Engineering Company Limited, which possesses the world’s first bio-engineering cornea, known as: “Acornea”, both successfully passed the examination and acceptance inspection procedures conducted by the Shenzhen Development and Reform Commission. With the support of Shenzhen’s policies on the development of strategic emerging industries, such projects shall, in attending to the developmental needs of Shenzhen’s bio-industry, serve to elevate our innovative capabilities in the field of tissue engineering, and, as well, cater to scientific research projects consigned by the relevant national, provincial and municipal departments.

China Regenerative Medicine International Limited (the “Company”, together with its subsidiaries, collectively the “Group”), is pleased to announce that the “Shenzhen Tissue Engineering Laboratory Project” and the “Tissue Engineering Cornea Product Development and Commercialization Project” undertaken by its subsidiary Shenzhen AiNear Cornea Engineering Company Limited (“AiNear”) both successfully passed the examination and acceptance inspection procedures conducted by the Shenzhen Development and Reform Commission (the “SDRC”). With the support of Shenzhen’s policies on the development of strategic emerging industries, such projects shall, in attending to the developmental needs of Shenzhen’s bio-industry, serve to elevate our innovative capabilities in the field of tissue

engineering, and, as well, cater to scientific research projects consigned by the relevant national, provincial and municipal departments.

In July and August 2018, the SDRC issued the Notice on the Acceptance of the Shenzhen Tissue Engineering Laboratory Project and the Notice on the Acceptance of the Tissue Engineering Cornea Product Development and Commercialization Project, respectively. Such notices clearly state that the relevant acceptance inspection was carried out in accordance with the relevant requirements of the Measures of Shenzhen Municipality for the Administration of Special Funds for the Development of Biological, Internet and New Energy Industries and the Provisional Measures of Shenzhen Municipality for Acceptance Inspection of Projects in Strategic Emerging Industries, and that both approved projects have gained inclusion in the Shenzhen's Special Financial Support Plan for the Development of Strategic Emerging Industries.

Shenzhen AiNear Cornea Engineering Company Limited, located in the Zhonghaixin Technology Park, Longgang District, Shenzhen, undertook the construction project. Having developed the world's first-ever bioengineered cornea known as: "Acornea", the company is a pivotal high-tech enterprise in Shenzhen, ranking among the top 500 modern industries in Guangdong Province. The project has established technology research platforms in four areas, namely: tissue engineering biomaterials, tissue engineering products, tissue engineering fundamental research and cell expansion and culture technology, and is engaged in the development and research of next-generation bioengineering corneal products, development and research of automated production equipment, registration and reporting of medical apparatus and products, cultivation of relevant technology talent and other functions.

Having successfully passed the acceptance inspection, Shenzhen Tissue Engineering Laboratory Project shall continue to be operated by Shenzhen AiNear Cornea Engineering Company Limited with Dr. Zhang Jinnan, chief technology officer of the Company, acting as the head of the laboratory. By focusing on the development trends of the tissue-engineering studies, the laboratory is committed to carrying out fundamental research in the field of tissue-engineering through leveraging the quality research standard of tissue-engineering in the PRC and considering the constraints being imposed while achieving the industrialization of tissue-engineering products to date. It shall also provide solutions to the commonality and key technologies research during the process of putting the scientific results in the tissue-engineering field into commercial use, and continue to commence development and research of bioengineered cornea and develop new cost-effective materials for manufacturing biodegradable stents and reagents with a view to facilitating the industrialization of the scientific research on tissue engineering in Shenzhen.

By Order of the Board
China Regenerative Medicine International Limited
Ray Yip
Executive Director

Hong Kong, 15 August 2018

As at the date of this announcement, the executive Director is Dr. Ray Yip; and the independent non-executive Directors are Mr. Chan Bing Woon, SBS, JP, Mr. Wong Yiu Kit Ernest and Dr. Fang Jun.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading. This announcement will remain on the “Latest Company Announcement” page of the GEM website at www.hkgem.com for at least seven days from the date of the publication and will be published on the website of the Company at www.crimi.hk.